South & Central America Coagulation Market Forecast to 2030 - Regional Analysis - by Disease Indications, Type, Technology, and End User

The South & Central America coagulation market was valued at US$ 401.01 million in 2022 and is expected to reach US$ 700.04 million by 2030; it is estimated to grow at a CAGR of 7.2% from 2022 to 2030.

Growing Organic and Inorganic Strategies by Key Market Players Fuel South & Central America Coagulation Market

Changing lifestyle habits and a growing geriatric population are among the major factors increasing the prevalence of blood disorders. Therefore, there is a growing demand for early diagnosis and treatment. Key players are taking several initiatives through various organic and inorganic strategies to enhance the quality of life of patient population.

• In June 2021, Trivitron Healthcare introduced NANO H5 and NANO H110, which help in monitoring diabetes, hemoglobin variations, and thalassemia.

• In February 2021, Siemens Healthineers and Sysmex Corporation renewed their agreement to supply, distribute, sell, and service hemostasis products across the world. The agreement also included an extension for multiple years. Further, Siemens Healthineers agreed to distribute Sysmex's automated blood coagulation analyzer, such as the CN-3000 and CN-6000.

• In July 2022, HORIBA Medical launched the latest Yumizen G800 and G1550 hemostasis analyzers, as well as a range of convenient ready-to-use reagents for common blood coagulation Offerings. With this expansion of its product line, HORIBA Medical now offers a comprehensive selection of hemostasis systems and advanced reagents for laboratories of all sizes and requirements.

Thus, the adoption of various organic and inorganic strategies by the key market players is expected to provide opportunities for the coagulation market growth during the forecast period.

South & Central America Coagulation Market Overview

The South & Central America coagulation market is segmented into Brazil, Argentina, and the Rest of South & Central America. The factors that are likely to contribute to the market growth in this region include government initiatives to expand the healthcare infrastructure and a surge in the population with various chronic diseases such as liver diseases and hemophilia.

Chile, Colombia, Peru, Cuba, Venezuela, and Bolivia are among the major countries in the Rest of South & Central America. The countries are strengthening their healthcare infrastructure by allowing new market participants to enter the market. Furthermore, governments of these countries are showing interest and spending significantly on upgrading their healthcare services, which has triggered the number of health facilities in these countries. Moreover, a rise in the geriatric population, coupled with the burgeoning prevalence of blood disorders, cardiovascular diseases, liver diseases, etc., highlights the importance of precise blood component analysis, which fuels the growth of the coagulation market in the Rest of South & Central America.

South & Central America Coagulation Market Segmentation

The South & Central America coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.

Based on disease indication, the South & Central America coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest South & Central America coagulation market share in 2022.

Based on type, the South & Central America coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger South & Central America coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the South & Central America coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger South & Central America coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the South & Central America coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest South & Central America coagulation market share in 2022.

By end user, the South & Central America coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest South & Central America coagulation market share in 2022.

Based on country, the South & Central America coagulation market is categorized into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America coagulation market in 2022.

F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San & Tic Ltd.Şti.; Siemens Healthineers AG; Sysmex Corp; and Transasia Bio-Medicals Ltd are some of the leading companies operating in the South & Central America coagulation market.